MYLAN N.V. news, videos and press releases
For more news please use our advanced search feature.
MYLAN N.V. - More news...
MYLAN N.V. - More news...
- Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
- Fair Fund to Compensate Certain Investors in Mylan N.V. Common Stock
- Fair Fund to Compensate Certain Investors in Mylan N.V. Common Stock
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viatris Inc. and Encourages Investors who Formerly Held Shares of Mylan Inc. (MYL) to Contact the Firm
- Mylan Wins Dismissal of Kansas EpiPen® Direct Purchaser Case
- Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action
- Mylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi
- Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc.
- Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris
- Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL
- Mylan to Present at the BofA Securities Virtual Global Healthcare Conference
- Mylan to Acquire Aspen's Thrombosis Business in Europe
- Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
- Mylan Initiates Voluntary Nationwide Recall of Four Lots of Amiodarone HCl Injection, USP and Tranexamic Acid Injection, USP Due to Carton Label Mix-Up
- Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera®
- ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action - MYL
- Mylan and Sesame Workshop Partner to Provide Socio-Emotional Support Resources to Families Impacted by COVID-19
- ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – MYL
- Mylan Reports Strong Second Quarter and First Half 2020 Results and Updates 2020 Guidance
- Mylan to Release Second Quarter 2020 Financial Results on Aug. 6, 2020
- ROSEN, A TOP RANKED INVESTOR FIRM, Reminds Mylan N.V. Investors of Important August 25 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MYL
- Viatris Reveals Branding to Reflect New Company's Transformative Strategy
- Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp)
- Mylan Initiates Voluntary Nationwide Recall of One Lot of Daptomycin for Injection, Due to the Presence of Particulate
- Mylan Secures Regulatory Approval for Remdesivir Lyophilized Powder for Injection 100 mg/vial in India for Restricted Emergency Use in COVID-19 Patients
- ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds Mylan N.V. Investors of Important August 25 Deadline in Securities Class Action – MYL
- MYL SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Mylan N.V. Investors With Losses Exceeding $11,000,000 of Class Action and Lead Plaintiff Deadline: August 25, 2020
- MYL SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Mylan N.V. Investors of Class Action and Lead Plaintiff Deadline: August 25, 2020
- ROSEN, A LONGSTANDING AND TOP RANKED GLOBAL INVESTOR FIRM, Announces Filing of Securities Class Action Lawsuit Against Mylan N.V.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MYL
- Mylan Shareholders Overwhelmingly Approve Proposed Combination with Upjohn